RPL3 and malignant colon neoplasm: In this study, we focused our study on examining the therapeutical potential of AdoMet to overcome drug resistance in the uL3∆HCT 116p53−/− cell line, a model of colon cancer cells resistant to conventional anticancer drugs including 5-FU, based on the absence of p53 and low levels of uL3 [10].